Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: Toward updated genotype-based dosage guidelines

Therapeutic Drug Monitoring

Volumn 35, Issue 5, 2013, Pages 608-616

  Elens, Laure ^a,b   Capron, Arnaud ^a,c   Van Schaik, Ron HN ^b   De Meyer, Martine ^c   De Pauw, Luc ^c   Eddour, Djamila C ^c   Latinne, Dominique ^c   Wallemacq, Pierre ^a,c   Mourad, Michel ^c   Haufroid, Vincent ^a,c  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

22 (rs35599367); CYP3A4; dosage guidelines; kidney transplantation; pharmacogenetics; tacrolimus

Indexed keywords

CREATININE; CYTOCHROME P450 3A4; GENOMIC DNA; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CREATININE CLEARANCE; DNA EXTRACTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; GENE DOSAGE; GENOTYPING TECHNIQUE; GRAFT RECIPIENT; GRAFT REJECTION; HOMOZYGOTE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; ALLELE; DOSE RESPONSE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; MIDDLE AGED;

ALLELES; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; TACROLIMUS;

EID: 84885021006     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318296045b     Document Type: Article

References (32)

1. Wallemacq P, Armstrong VW, Brunet M, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: Report of the European consensus conference. Ther Drug Monit. 2009;31:139-152
2. MacPhee IA, Fredericks S, Tai T, et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant. 2004;4:914-919
3. Undre NA. Pharmacokinetics of tacrolimus-based combination therapies. Nephrol Dial Transplant. 2003;18(suppl 1):i12-i15
4. Undre NA, van Hooff J, Christiaans M, et al. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc. 1999;31:296-298
5. Dai Y, Hebert MF, Isoherranen N, et al. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos. 2006;34:836-847
6. Kamdem LK, Streit F, Zanger UM, et al. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem. 2005;51:1374-1381
7. Hines RN. Ontogeny of human hepatic cytochromes P450. J Biochem Mol Toxicol. 2007;21:169-175
8. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27:383-391
9. Elens L, Capron A, Kerckhove VV, et al. 1199G.A and 2677G.T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation. Pharmacogenet Genomics. 2007;17:873-883
10. Goto M, Masuda S, Kiuchi T, et al. CYP3A5. 1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics. 2004;14:471-478
11. Haufroid V, Mourad M, Van Kerckhove V, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics. 2004;14:147-154
12. Haufroid V, Wallemacq P, VanKerckhove V, et al. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: Guidelines from an experimental study. Am J Transplant. 2006;6:2706-2713
13. Hesselink DA, van Schaik RH, Van Der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther. 2003;74:245-254
14. Macphee IA, Fredericks S, Mohamed M, et al. Tacrolimus pharmacogenetics: The CYP3A5. 1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. Transplantation. 2005;79:499-502
15. Thervet E, Anglicheau D, King B, et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-To-dose ratio in renal transplant recipients. Transplantation. 2003;76:1233-1235
16. Tsuchiya N, Satoh S, Tada H, et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation. 2004;78:1182-1187
17. Zheng H, Webber S, Zeevi A, et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant. 2003;3:477-483
18. Zheng H, Zeevi A, Schuetz E, et al. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. J Clin Pharmacol. 2004;44:135-140
19. Hesselink DA, van Schaik RH, van Agteren M, et al. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-Treated renal transplant recipients. Pharmacogenet Genomics. 2008;18:339-348
20. Thervet E, LoriotMA, Barbier S, et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther. 2010;87:721-726
21. Wang D, Guo Y, Wrighton SA, et al. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 2011;11:274-286
22. Elens L, Bouamar R, Hesselink DA, et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem. 2011;57:1574-1583
23. Elens L, van Schaik RH, Panin N, et al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics. 2011;12:1383-1396
24. Capron A, Mourad M, De Meyer M, et al. CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation. Pharmacogenomics. 2010;11: 703-714
25. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41
26. Wallemacq P, Goffinet JS, O'Morchoe S, et al. Multi-site analytical evaluation of the Abbott ARCHITECT tacrolimus assay. Ther Drug Monit. 2009;31:198-204
27. Elens L, van Gelder T, Hesselink DA, et al. CYP3A4. 22: Promising newly-identified CYP3A4 variant allele for personalizing pharmacotherapy. Pharmacogenomics. 2013;14:47-62
28. Chan C, Maurer J, Cardella C, et al. A randomized controlled trial of verapamil on cyclosporine nephrotoxicity in heart and lung transplant recipients. Transplantation. 1997;63:1435-1440
29. Duggan KA, Macdonald GJ, Charlesworth JA, et al. Verapamil prevents post-Transplant oliguric renal failure. Clin Nephrol. 1985;24:289-291
30. Kuypers DR, Neumayer HH, Fritsche L, et al. Calcium channel blockade and preservation of renal graft function in cyclosporine-Treated recipients: A prospective randomized placebo-controlled 2-year study. Transplantation. 2004;78:1204-1211
31. Neumayer HH, Wagner K. Prevention of delayed graft function in cadaver kidney transplants by diltiazem: Outcome of two prospective, randomized clinical trials. J Cardiovasc Pharmacol. 1987;10(suppl 10): S170-S177
32. Elens L, Hesselink DA, van Schaik RH, van Gelder T. The CYP3A4. 22 allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations. Br J Clin Pharmacol. 2013; 75:1545-1547